BOULDER, Colo.– Biodesix, Inc. today announces a collaborative agreement with Bruker Daltonics to support Biodesix’ VeriStrat diagnostic test as well as future diagnostic tests based on matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. VeriStrat is a novel, multivariate serum protein test that helps oncologists personalize therapy for patients with lung cancer. The new collaboration advances the companies’ existing relationship concerning use of Bruker’s state of the art MALDI-TOF instruments with VeriStrat and Biodesix’ other clinical diagnostics in development. The agreement provides avenues for valuable hardware and software/applications support as well as access to the latest in instrument designs and improvements.

MALDI-TOF mass spectrometry is a powerful analytical platform that can provide detailed and discriminating information about complex biological samples, but with relatively simple sample preparation and high throughput. The combination of Biodesix’ platform technology, including Biodesix’ sophisticated and proprietary data analysis algorithms, and Bruker instruments, valued for their outstanding performance, reliability, and innovative designs forms the basis for a robust clinical diagnostics platform.

“We are pleased to solidify our relationship with one of our key partners with this new agreement,” stated Gary Pestano, PhD, Head of Product Development and Lab Operations at Biodesix. “The support we receive from Bruker will substantially benefit both the delivery and development of our diagnostic tests.”

Gary Kruppa, Vice President for Business Development at Bruker Daltonics commented, “We have been impressed with Biodesix’ capabilities for development of MALDI-TOF mass spectrometry based diagnostic assays. We are delighted to work even more closely with Biodesix to support their goals, which of course we also expect will increase the market for Bruker’s innovative MALDI-TOF mass spectrometers in diagnostics.”

About Biodesix

Biodesix is a molecular diagnostics company advancing the development of innovative products for personalizing medicine. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring and better therapeutic guidance, which may lead to improved patient outcomes. Biodesix discovers, develops and commercializes multivariate protein diagnostics based on their proprietary mass spectrometry-based discovery platform. VeriStrat, a multivariate serum protein test, is Biodesix’ first product developed with this technology. The commercially available test provides oncologists with information to help them select between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Tests are processed in Biodesix’ CLIA-certified laboratory and results are reported in less than 72 hours. In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve utility of therapeutic agents. For more information on VeriStrat, please visit www.VeriStratSupport.com. For more information about Biodesix, please visit www.Biodesix.com.